Supports long-term weight loss In the STEP 1 trial, participants taking semaglutide lost an average of almost 15% of their body weight compared to about 2% in the placebo group
Keeping your blood sugar level within normal ranges
Low doses of GLP-1 receptor agonists are really powerful for reducing A1C, or the average glucose in the blood, said Buse, who is also co-director of the NC Translational and Clinical Sciences Institute
But expectations need to stay grounded
In response, the UK government has started gathering participants for a large-scale study to understand the root cause
However, their benefits extend beyond blood sugar control, offering promising results for weight management, cardiovascular health, and even cognitive function